Share This

PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
FaceHeart Received Another FDA Clearance for its Contactless Video-Based Vital Sign Measurement of Respiratory Rate
Developed by FaceHeart, FH Vitals SDK-RR has obtained FDA Clearance. This is the second 510(k) class II SaMD (Software as a Medical Device) FaceHeart received from the FDA. FaceHeart Vitals™ is a video-based, ...
2025-05-01T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
No-Drama Modern Parenting: GROWNSY Shares 10 Must-Have Upgrades for Modern Moms This Mother's Day
Because modern moms don't need clichés, they need real solutions. ...
2025-05-01T    Health Care/Hospital   Household/Consumer/Cosmetics   Retail 
A global study led by CUHK and the University of Calgary charts four-stage evolution of Inflammatory Bowel Disease
HONG KONG , May 1, 2025 /PRNewswire/ -- An international consortium led by The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and the University of Calgary in Canada ...
2025-05-01T    Education   Health Care/Hospital   Higher Education   Infectious Disease Control 
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China , May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III ...
2025-05-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Preserving fertility and optimising care for the one in seven women suffering from endometriosis
SINGAPORE , May 1, 2025 /PRNewswire/ -- Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help ...
2025-05-01T    Health Care/Hospital   Medical/Pharmaceuticals 
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea , May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd. , a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food ...
2025-05-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Natus announces integration of InVisus Pro NMUS into Natus Elite software
MIDDLETON, Wis. , May 1, 2025 /PRNewswire/ -- Natus Medical Incorporated has announced its InVisus Pro Neuromuscular Ultrasound system can now be seamlessly integrated with all Natus EMG systems via ...
2025-05-01T    Computer Software   Computer/Electronics   Health Care/Hospital   Medical Equipment 
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI , April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan University, ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Showcasing the future of ophthalmic research at ARVO 2025: ...
2025-04-30T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
SHANGHAI , April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...
2025-04-30T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.